Drug
Acoramidis is a transthyretin stabilizer used in transthyretin amyloid cardiomyopathy.
Sources: FDA label · 3 registered trials
FDA-approved indications
Source: Attruby label (DailyMed), label dated Jun 29, 2026
Dosing is left to the label.
Primary results of the trial behind the evidence on acoramidis, as each trial’s own publication reports it.
acoramidis vs placebo · 632 patients · N Engl J Med 2024
Primary outcome: The four-step primary hierarchical analysis included death from any cause, cardiovascular-related hospitalization, the change from baseline in the N-terminal pro-B-type natriuretic peptide (NT-proBNP) level, and the change from baseline in the 6-minute walk distance
“win ratio was 1.8 (95% confidence interval [CI], 1.4 to 2.2)”
Results are quoted from each trial’s primary publication abstract (PubMed); the trial name links to the paper. Ratios below 1 favour the intervention.
Registered trials with acoramidis in an arm, past phase 1 with at least 50 participants: the largest in each indication, newest first. Trials that give it only as the comparator are tagged; trials that give it in every arm are listed last.
NCT07298044 · Phase 4 · Recruiting · 50 participants · started 2026
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)
NCT06563895 · Phase 3 · Recruiting · 582 participants · started 2025
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
NCT03860935 · Phase 3 · Completed · 632 participants · started 2019
Source: ClinicalTrials.gov registry records.
Class membership: Synapse curated drug classes
A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.
Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.
Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.
The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.